ClinicalTrials.gg
RecruitingNCT06354465Updated Apr 9, 2024

Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews

An observational study in Opioid Use Disorder, Criminal Justice and Treatment Adherence and Compliance, sponsored by Lifespan. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-09.

Sponsored by Lifespan · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
25
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,223 studies in Opioid-Related Disorders with a site in United States — 246 open to participants now, 316 under way, 18 of them phase 3. Opioid-Related Disorders · United States.

Planned enrollment
92nd of 122
25 · median 85
Started
2023
with 83 others
Observational
122 of 1,223
29 open now
Primary completion
2024-07
later than 12 of 315 live
Registered
995th of 1,223
by date

Among the 1,223 studies in Opioid-Related Disorders with a site in United States, this one is the 92nd largest by planned enrollment of the 122 observational ones that give a count, is one of 84 that started in 2023, is one of 122 observational ones, reaches primary completion later than 12 of the 315 other live ones, and was the 995th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

246 of the 1,223 studies in Opioid-Related Disorders with a site in United States are open now. Recruiting first, the newest first:

241 more — sign in →

All 246 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,223 studies in Opioid-Related Disorders with a site in United States, or all of them as a file.
02

Study summary

This qualitative study investigates the potential benefits and challenges of using a once-a-month injectable medication, known as extended-release buprenorphine (XR-B), to treat individuals with opioid use disorder (OUD) within a correctional setting. The research aims to understand if XR-B can be a feasible and effective alternative to the standard daily treatment and to identify which groups within the prison population may benefit the most from this treatment. In-depth interviews are conducted with incarcerated individuals and relevant stakeholders.

03

Conditions studied

  • Opioid Use Disorder
  • Criminal Justice
  • Treatment Adherence and Compliance

Keywords

  • addiction
  • criminal justice
  • Medications for opioid use disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Incarcerated individuals include participants in the RIDOC MOUD program.

Organizational stakeholders inlcude clinicians, Wardens, leadership and/or other staff involved in the MOUD program.

Eligibility criteria

Incarcerated individuals, inclusion criteria:

  • English speaking
  • Over the age of 18
  • Diagnosed with opioid use disorder

Incarcerated individuals, Exclusion Criteria:

  • Diagnosed with "Severe, Persistent, Mental Illness (SPMI)" Rationale for Exclusion: These individuals suffer from severe mental health disease and therefore warrant greater protection, have greater risk for coercion, and offer insights to severe co-diagnosis treatment that, while important, remain outside the scope of general MAT implementation.

Organizational Stakeholders, Inclusion Criteria:

  • Employed or contracted by Rhode Island Department of Corrections (for organizational staff interviews) and involved with the Medication for Addiction Treatment (MAT) program

Organizational Stakeholders, Exclusion Criteria:

  • If not permitted by their organizational union to participate
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
25 participants (estimated)
Patient registry
No

Groups and cohorts

  • Incarcerated Individuals

    Incarcerated individuals will be recruited across the Rhode Island Department of Corrections (RIDOC)facility during the required group sessions for treatment; this is consistent with previous NIH-funded studies at RIDOC. The interviews will be described and participants will be able to sign up confidentially. Participants who are eligible for Medications for Opioid Use Disorder (MOUD) but decide not to pursue treatment will still be interviewed to provide better understanding of the key factors that drive program participation. These individuals can be recruited through routine clinical care by addiction medicine providers. Every precaution will be taken to ensure confidentiality and protection of all participants.

  • Stakeholders

    Organizational stakeholders (clinicians, Wardens, leadership and/or other staff) will be recruited through snowball sampling. I will individually approach leaders of each facility to recruit correctional individuals interested in participating and will also allow participants to confidentially sign up at administrative meetings related to Medication for Addiction Treatment (MAT).

06

What researchers measure

Primary outcomes

  1. Qualitative Transcripts

    A directed content analysis will identify key themes in structured interviews

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Given the sensitivity of data, some individual data may be censored but will be available to other researchers in aggregate.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Jul 2024, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2024
First posted
Apr 9, 2024
StartActual
Jul 1, 2023
Primary completionEst.
Jul 1, 2024
CompletionEst.
Jul 1, 2024
Last update
Apr 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06354465
Lead sponsor
Lifespan
Responsible party
Justin Berk (Assistant Professor, Lifespan) — Principal investigator
First posted
Apr 9, 2024
Start date
Jul 1, 2023
Primary completion
Jul 1, 2024 (estimated)
Completion
Jul 1, 2024 (estimated)
Last update
Apr 9, 2024

Study contacts

Justin Berk, MD
Contact
justin_berk@brown.edu
8064333960
Justin Berk, MD
principal investigator · Lifespan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion